NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional) | PAR 21 101

FAQs: NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional) - PAR-21-101

What is this funding opportunity?

This opportunity is the NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional), Funding Opportunity Number PAR-21-101. It is an NIH cooperative agreement that supports a structured planning phase for complex, hypothesis-driven, multi-center clinical studies within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

What is the purpose of a U34 planning award in this program?

The U34 supports the practical work needed to move a promising multi-site clinical study from concept to an implementation-ready package. The planning phase is intended to reduce avoidable failures later by stress-testing the scientific rationale and operational readiness before a full-scale implementation effort is launched.

What does "high-risk" mean in the context of this opportunity?

"High-risk" generally signals studies that are complex, logistically demanding, novel in approach, or uncertain in feasibility without deliberate upfront planning and standardization. The U34 planning step is designed to address those risks through rigorous protocol and operations development.

What kinds of studies does this U34 support?

The proposed clinical study should be hypothesis-driven and multi-center (more than one study site). It should also fall within NIDDK mission areas (such as diabetes, endocrinology and metabolic diseases, digestive diseases, nutrition-related disorders within scope, and kidney and urologic diseases).

Does the study have to be multi-center?

Yes. The program is specifically aimed at multi-center clinical studies, defined here as having more than one study site.

Is this award meant to fund the actual conduct of a large multi-center trial?

No. The U34 is positioned as a planning mechanism. It is meant to fund planning and documentation work (for example, protocol finalization and operational materials), not the full conduct of a large, multi-center clinical trial or study.

What are the main goals or expected outcomes of the U34 planning phase?

Based on the description, the U34 is intended to: enable early peer review of the study rationale; allow thorough assessment of the design and protocol (including endpoints, eligibility criteria, recruitment strategy, and statistical approach); support development of essential study conduct documents (especially a Manual of Operations); and build other operational components needed to run a consistent, high-quality multi-center study.

What is meant by "two-part pathway" for these studies?

NIDDK describes a two-part approach for certain high-risk multi-center clinical studies. The first part is a structured planning phase supported by a U34 award. The second part is a later implementation effort (typically via a subsequent application) if the planning work produces an implementation-ready package and the project moves forward.

What is a cooperative agreement, and how is it different from a standard NIH grant?

This opportunity uses a cooperative agreement funding instrument, which implies a more active partnership between the awardee and NIDDK during the planning period than would be typical under a standard investigator-initiated grant mechanism.

Is it recommended to contact NIDDK before applying?

Yes. Consultation with NIDDK scientific staff before submitting a U34 application is strongly encouraged. This reflects the need for early alignment on feasibility, scope, institute priorities, and planning-phase deliverables that position the project for a potential next stage.

What types of activities can U34 funds be used for during planning?

The U34 is described as supporting detailed, practical planning work such as refining the study design and protocol; evaluating feasibility of endpoints, eligibility criteria, recruitment strategies, and the statistical approach; and developing core operational materials needed for consistent conduct across multiple sites.

What is the Manual of Operations (MOO), and why is it important here?

The Manual of Operations is highlighted as a key study conduct document typically created or refined during the U34 phase. It generally lays out standardized procedures across sites for recruitment, consent, intervention delivery, outcome assessment, safety monitoring, data handling, and quality assurance. The goal is to ensure consistent implementation across all centers.

Besides the MOO, what other "building blocks" are commonly developed during the U34 phase?

The opportunity points to additional operational components such as training plans, site workflows, data management processes, and other operational materials that often determine whether multi-center studies can be run consistently and successfully.

What role does peer review play in this planning award?

The U34 is intended to enable early peer review of the study rationale so reviewers can assess whether the research question is important, timely, and strong enough to justify the complexity and cost of a multi-center effort. Peer review also supports evaluation of the proposed design and protocol feasibility.

What organizational types are eligible to apply?

Eligibility is broad and includes many U.S.-based organization types, including: state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations other than federally recognized governments; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; and small businesses.

Are certain institution categories explicitly called out as eligible?

Yes. The opportunity explicitly mentions additional eligible categories such as Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISI); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; eligible federal agencies; regional organizations; Indian/Native American tribal governments that are not federally recognized; and U.S. territories or possessions.

Can foreign (non-U.S.) institutions apply?

No. Non-domestic (non-U.S.) entities (foreign institutions) are not eligible to apply under this opportunity.

Are non-domestic components of U.S. organizations eligible?

No. The notice states that non-domestic components of U.S. organizations are not eligible.

Are any international elements allowed at all?

Yes, the opportunity allows "foreign components" as defined in the NIH Grants Policy Statement. This means a U.S. applicant may include certain eligible international elements when justified and structured according to NIH policy, even though the applicant organization itself must be domestic.

What is the activity area and CFDA number associated with this opportunity?

The opportunity is categorized under the Food and Nutrition, Health activity area and lists CFDA number 93.847.

What is the maximum award amount (award ceiling) listed?

The listed award ceiling is $225,000.

What is the original closing date shown for this opportunity?

The original closing date shown is 2024-02-15.

Does "Clinical Trial Optional" mean the application must include a clinical trial?

The title indicates "Clinical Trial Optional," which signals that a clinical trial is not necessarily required for every application under this announcement. The focus described is on planning a complex, hypothesis-driven, multi-center clinical study within NIDDK's mission.

What is the practical value of doing this U34 planning step before pursuing implementation funding?

The planning phase is described as a way to reduce avoidable failures by validating the scientific rationale and testing operational readiness. It helps ensure the study has credible, standardized procedures across sites and the documentation needed for consistent execution, which can strengthen a later implementation application if pursued.

What should an application be structured around during the planning period?

The description emphasizes that planning should be organized around deliverables that clearly position the project for the next stage. Examples of deliverables mentioned include a refined protocol and design, a Manual of Operations, and operational materials such as training plans, site workflows, and data management processes.